Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (241-250 of 302) with videos related to

Pageof 31
Sort By:
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
British Journal of Haematology|May 10, 2018
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximabKatie Y Zhu, Kevin W Song, Joseph M Connors, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant groupDiego Villa, Michael Crump, Tony Panzarella, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
British Journal of Haematology|January 31, 2021
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysisPaolo Strati, Phoebe T M Cheng, Raphael E Steiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study AssociationRobert Kridel, Luc Xerri, Bénédicte Gelas-Dore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphomaJaveed Iqbal, Vishala T Neppalli, George Wright, et al.
Blood|October 27, 2022
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma populationWaleed Alduaij, Brett Collinge, Susana Ben-Neriah, et al.
Pageof 31

Showing results (241-250 of 302) with videos related to

Sort By:
Pageof 31
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
British Journal of Haematology|May 10, 2018
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximabKatie Y Zhu, Kevin W Song, Joseph M Connors, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant groupDiego Villa, Michael Crump, Tony Panzarella, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
British Journal of Haematology|January 31, 2021
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysisPaolo Strati, Phoebe T M Cheng, Raphael E Steiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study AssociationRobert Kridel, Luc Xerri, Bénédicte Gelas-Dore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphomaJaveed Iqbal, Vishala T Neppalli, George Wright, et al.
Blood|October 27, 2022
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma populationWaleed Alduaij, Brett Collinge, Susana Ben-Neriah, et al.
Pageof 31